Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of six systematic review(s)/meta-analysis(es). ^[1-6]
• Fruquintinib demonstrated improved overall survival (OS) compared to best supportive care (BSC), with results comparable to TAS-102 and regorafenib, although no significant differences in OS were observed among these drugs in some studies.
• Fruquintinib showed superior progression-free survival (PFS) compared to BSC and exhibited a better PFS in specific subgroups, such as patients with wild-type KRAS. Fruquintinib also demonstrated significant superiority for PFS compared with TAS-102 in several studies.
• Fruquintinib was associated with an improved disease control rate (DCR) compared to TAS-102, with relative superiority in terms of achieving disease control in several reports.
• Fruquintinib was associated with a higher incidence of serious adverse events (SAES) compared to TAS-102 or regorafenib.
• There were no significant differences in the incidence of all-grade adverse events (AES) or grade 3-5 AEs among fruquintinib, TAS-102, and regorafenib, as observed in multiple documents.
• Subgroup analysis showed that TAS-102 plus bevacizumab ranked first in overall survival (OS) benefit across various subgroups, including age, gender, ECOG performance status (PS), and time from initial diagnosis of metastatic disease. Document 4 noted that fruquintinib demonstrated better progression-free survival (PFS) in the wild-type KRAS subgroup compared to other treatments, with good tolerability.